This short video explains how CAR-T cell Therapy harnesses a patient's own cells to fight cancer.
Animation by Maja Divjak
Find out more information on how CAR-T cell therapy works
Current CAR-T cell therapy treatments (standard of care and clinical trials)
Subsidised access to CAR-T therapy is available for eligible Australians:
Adult patients with relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL)
Paediatric or young adult (up to 25 years) patients with relapsed or refractory Acute Lymphoblastic Leukaemia (ALL).
The following CAR-T cell therapies are currently offered as standard of care:
Further CAR-T therapy treatments
Further CAR-T therapies for the treatment of additional cancers are under review.
Patient prioritisation meeting
The CoE CIT hosts a national, weekly CAR-T patient prioritisation meeting where new patient referrals are discussed nationally to ensure fair and equitable access to standard of care CAR-T cell therapies, as well as available clinical trials.
CAR-T cell cherapy contact
Health practitioners can find out more information about access to CAR-T therapy for patients by emailing